ProKidney Q2 Loss Widens to $48M as Trial Costs Surge; Enrollment Milestone Hit
PROK is trading near its 52-week low of $1.45 (13% above the low).
Summary
ProKidney's Q2 operating loss widened to $48.37 million from a year ago, driven by a jump in clinical and manufacturing costs for its lead PROACT 1 trial. Operating expenses hit $48.52 million, reflecting the heavy spend on the Phase 3 study. The company completed enrollment for the accelerated approval efficacy analysis, a key operational milestone, with topline eGFR slope results now expected in Q2 2027. Full enrollment remains on track for the second half of 2026. Cash is sufficient only into mid-2027, keeping financing risk front and center. This follows the Q1 report that already flagged rising burn and a limited runway.
At the time of this announcement, PROK was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $510.5M. The 52-week trading range was $1.45 to $3.48. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.